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ABSTRACT
The incidence of nosocomial disease caused by Gram-negative pathogens is increasing, and infections
caused by Enterobacter, Klebsiella, Acinetobacter, Escherichia coli and Pseudomonas aeruginosa are more
commonly refractive to traditional antimicrobial agents, including aminoglycosides, ﬂuoroquinolones
and broad-spectrum cephalosporins. The most important mechanism of resistance to b-lactam
antibiotics among Gram-negative bacilli involves the production of b-lactamases. Extended-spectrum
b-lactamases are particularly worrisome, since they are often associated with multidrug resistance
phenotypes, which can pose a signiﬁcant therapeutic challenge. Novel agents for the treatment of Gram-
negative infections are uncommon, as recent emphasis has been placed on the development of agents
targeting drug-resistant strains of Gram-positive bacteria, e.g., streptococci, enterococci and staphylo-
cocci. Tigecycline, a semi-synthetic derivative of minocycline, has a unique and novel mechanism of
action, which not only allows this agent to overcome the well-known tet gene-encoded resistance
mechanisms, but also maintains its activity against Gram-negative pathogens producing a broad array
of extended-spectrum b-lactamases. Tigecycline is the ﬁrst example of a new class of glycylcyclines with
activity against a wide range of clinically important Gram-negative pathogens. Tigecycline has potent
antimicrobial activity, and has been associated with an excellent therapeutic response in animal infection
models and recently reported clinical trials, which reﬂect the effectiveness of tigecycline against
pathogens causing intra-abdominal, skin and soft-tissue infections, including susceptible or multidrug-
resistant strains of most Enterobacteriaceae, as well as anaerobic pathogens.
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INTRODUCTION
Gram-negative pathogens continue to play an
important role in the aetiology of nosocomial
disease, including pneumonia, urinary tract infec-
tion, surgical site infection and infections among
intensive care unit (ICU) patients, with the Gram-
negative organisms isolated most commonly
being Klebsiella spp., Enterobacter spp., Pseudomon-
as spp., Acinetobacter spp. and Escherichia coli [1].
The recent increase in extended-spectrum b-lac-
tamase (ESBL)-producing Enterobacteriaceae in
the community and private healthcare centres
also gives cause for concern [2,3]. The discharge of
hospitalised patients carrying ESBL-producing
Enterobacteriaceae, and the selection of ESBL-
producing strains from gastrointestinal ﬂora ex-
posed to broad-spectrum antimicrobial agents,
probably contributes to the spread of these resist-
ant pathogens in the community [4].
Bacterial resistance among Gram-negative
pathogens continues to be a challenging clinical
problem [5]. Esch. coli isolates resistant to ciproﬂ-
oxacin, amoxycillin and tetracyclines, Klebsiella
pneumoniae isolates with reduced susceptibility to
ceftazidime, and Citrobacter freundii and Enterob-
acter spp. with high-level third-generation cepha-
losporin resistance mediated by AmpC-type
b-lactamases, are now reported commonly [4,6].
More recent reports have also noted increasing
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resistance rates among Acinetobacter spp., Pseudo-
monas aeruginosa and Stenotrophomonas maltophilia
[6–8]. Traditional therapy for Gram-negative bac-
terial infections has included aminoglycosides,
b-lactams, ﬂuoroquinolones, folate antagonists
and tetracyclines. However, increased bacterial
resistance has diminished the clinical effective-
ness of many of these antimicrobial agents,
particularly in settings where multidrug resist-
ance is prevalent.
Bacterial resistance to antibiotics can occur via
several pathways, involving altered target sites,
up-regulated targets, inactivating enzymes or
decreased intracellular concentrations (either by
increased efﬂux or reduced drug penetration).
Multiple resistance mechanisms can occur among
Gram-negative bacteria speciﬁcally, particularly
against b-lactams, ﬂuoroquinolones and macro-
lides. b-Lactamases can be especially problematic,
given their wide distribution among bacterial
species in general (streptococci, Helicobacter pylori
and most enterococci excepted) and their notable
potency against penicillins, cephalosporins,
monobactams and ⁄ or carbapenems. There have
been increasing reports of Gram-negative bacteria
carrying multiple b-lactamases (e.g., an ESBL + a
plasmid-encoded AmpC-type enzyme + a car-
bapenemase), which can effectively result in
resistance to most or all b-lactams.
Tigecycline is the most recently developed
analogue of a newly introduced, semi-synthetic
broad-spectrum antibiotic class, the glycylcy-
clines. Tigecycline has activity against a wide
range of Gram-negative, Gram-positive and
anaerobic bacteria, including strains with
well-deﬁned resistance mechanisms [8–12]. In
addition, tigecycline possesses activity against
clinical isolates resistant to tetracyclines that
carry tet genes encoding either efﬂux or ribo-
somal protection resistance mechanisms [13].
Tigecycline has a different mechanism of inter-
action with the bacterial ribosome (see below),
which clearly differentiates tigecycline from the
structurally related tetracyclines and contributes
to the enhanced clinical effectiveness of this new
agent.
This review discusses some of the most
important resistance mechanisms found among
Gram-negative bacteria, together with the ob-
served in-vitro potency and clinical activity of
tigecycline against problematic Gram-negative
pathogens.
b -LACTAM RESISTANCE
MECHANISMS AMONG
GRAM-NEGATIVE BACTERIA
Resistance in Gram-negative bacteria is related to
multiple factors, including the production of a
wide range of b-lactamases, e.g., the AmpC,
TEM ⁄ SHV and OXA types, with the latter two
types including enzymes with ESBL activity, and
metallo-b-lactamases (MBLs) with activity against
carbapenems (e.g., the VIM and IMP families of
enzymes). Resistance may also be induced as a
result of elevated enzyme production, coupled
with a decrease in porin production or increased
efﬂux.
The functional and molecular characteristics of
the major groups of b-lactamases have been well-
documented; however, the rates of evolution and
genetic exchange of b-lactamase genes are very
rapid, resulting in sudden changes of resistance
and diverse patterns of resistance [3,14]. ESBLs
are plasmid-mediated b-lactamases, predomin-
antly belonging to Bush class A, that have, to
date, been described only in Gram-negative bacilli
[15]. ESBLs are capable of efﬁciently hydrolysing
penicillins, narrow-spectrum cephalosporins (ce-
fepime, etc.), many extended-spectrum cephalo-
sporins, the oxyimino cephalosporins (cefotaxime,
ceftazidime) and monobactams (aztreonam). The
ﬁrst ESBLs to emerge were mutants of TEM-1,
TEM-2 and SHV-1, but none has been described
to date that is capable of hydrolysing cephamycin
or carbapenems. ESBL-producing isolates are
most commonly Klebsiella spp., predominantly
Kleb. pneumoniae, and Esch. coli. Typically, ESBLs
are mutant, plasmid-mediated b-lactamases, de-
rived from older, broad-spectrum b-lactamases
(e.g., TEM-1, TEM-2, SHV-1), and have an exten-
ded substrate proﬁle that permits hydrolysis of all
cephalosporins, penicillins and aztreonam.
Although produced most commonly by Klebsiella
spp. and Esch. coli, they may also occur in other
Gram-negative bacteria, including Ps. aeruginosa
[15–18]. Arguably, the most important group of
ESBLs is the CTX-M group, which appears to
have evolved following the movement of chro-
mosomal b-lactamase genes, which are normally
intrinsic to Kluyvera spp., via horizontal gene
transfer [19]. In contrast, Bush class C enzymes
are primarily chromosomal rather than plasmid-
mediated. Class C b-lactamases (predominantly
AmpC) are resistant to b-lactamase inhibitors,
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and mutations in the AmpC regulatory gene,
which occur at a high frequency in Enterobacter
cloacae, can result in high-level constitutive AmpC
production, which produces resistance to all
b-lactams except carbapenems. Plasmid-mediated
AmpC b-lactamases can arise from the transfer of
chromosomal genes encoding an inducible AmpC
b-lactamase (predominantly from Enterobacter
spp., Morganella spp. and Citrobacter) to plasmids
[20]. Such transfer events have resulted in the
appearance of plasmid-mediated AmpC-type
b-lactamases in isolates of Esch. coli, Kleb. pneu-
moniae, Salmonella spp., C. freundii, Enterobacter
aerogenes and Proteus mirabilis. Commonly repor-
ted plasmid-encoded AmpC enzymes include
MIR-1, CMY-2, BIL-1, FOX-1, LAT-1, FEC-1,
MOX-1 and CMY-3 [21,22]. ESBLs and plasmid-
mediated AmpC b-lactamases are typically
associated with multidrug resistance, as other
antimicrobial resistance genes often reside on the
same plasmids as the ESBL and AmpC genes.
Bush class B b-lactamases include metallo-
proteases capable of hydrolysing carbapenems
such as imipenem and meropenem. This class of
b-lactamase was ﬁrst reported in 1998 among
isolates of Ps. aeruginosa and Serratia marcescens
from Japan [23]. In addition to carbapenems, the
isolates were resistant to other b-lactams and
b-lactamase inhibitors, with the exception of
aztreonam.
Surveillance initiatives have identiﬁed VIM and
IMP MBLs in Acinetobacter spp., Ps. aeruginosa,
Steno. maltophilia and Enterobacteriaceae [24].
Remarkably high rates of MBL production have
been reported in Korea, where 11.4% and 14.2%
of imipenem-resistant isolates of Ps. aeruginosa
and Acinetobacter baumannii, respectively, were
MBL producers [25]. The VIM-2 MBL has spread
extensively to become the predominant European
MBL, but has also been found in the Middle and
Far East, and recently in the USA [23].
PREVALENCE OF TET RESISTANCE
MECHANISMS AMONG
GRAM-NEGATIVE BACTERIA
Table 1 summarises the distribution of tet efﬂux
and ⁄ or ribosomal protection resistance genes
currently known to exist among selected genera
of Gram-negative bacteria [26]. Although the
earliest and most frequently described tet deter-
minants, i.e., tetA, tetB and tetM, were selected by
heavy use of tetracycline and oxytetracyclines,
later derivatives of the tetracycline class, e.g.,
doxycycline and minocycline, were also rendered
ineffective by the same tet resistance genes,
leading to an ultimate reduction in the clinical
utility of this class of antimicrobial agents.
TIGECYCLINE ACTIVITY AGAINST
GRAM-NEGATIVE PATHOGENS
Tigecycline is a glycylcycline, and is the ﬁrst of
this novel class of antimicrobial agents. Tigecy-
cline has broad-spectrum activity against suscept-
ible and commonly encountered resistant strains
of Gram-negative pathogens, as well as Gram-
positive aerobes, anaerobes and atypical patho-
gens. Developed for use as a parenteral agent
against challenging nosocomial infections, tigecy-
cline is one of the few agents developed recently
that has enhanced activity against problematic
Gram-negative organisms.
Tigecycline is a 9-t-butylglycylamido semi-syn-
thetic derivative of minocycline. This structural
modiﬁcation is responsible for the observed dif-
ferences in ribosomal binding-site afﬁnities and
orientation for tigecycline compared with either
minocycline or tetracycline. Early work demon-
strated that tigecycline binds to the same target
within the 30S and 70S ribosomes, but with ﬁve-
fold and >100-fold greater afﬁnity than minocy-
cline and tetracycline, respectively [27,28]. More
recent analyses suggest that the binding orienta-
tion of tigecycline with the ribosomal A subunit
differs from that of tetracycline, resulting in the
observed increase in binding afﬁnity and a one-to-
two log inhibition of protein synthesis [29].
Additional interactions between tigecycline, H34
and residues of the 30S ribosomal subunit have
not been observed with tetracycline, providing
Table 1. Distribution of tet resistance genes among selec-
ted Gram-negative bacteria
Efﬂux Ribosomal protection and/or efﬂux
Single genes
Chlamydia: tet(C) Eikenella: tet(M)
Stenotrophomonas: tet(35) Campylobacter: tet(O)
Two or more genes
Providencia: tet(B), (E), (G) Haemophilus: tet(B), (K), (M), (A)
Enterobacter: tet(B), (C), (D), (M) Bacteroides: tet(M), (Q), (X), (36)
Citrobacter: tet(A), (B), (C), (D) Acinetobacter: tet(A), (B), (H), (M), (39)
Proteus: tet(A), (B), (C), (J) Neisseria: tet(M), (O), (Q), (W), (B)
Klebsiella: tet(A), (B), (C), (D), (M)
Escherichia: tet (A), (B), (C), (D), (E), (G), (M), (Y)
Pseudomonas: tet (A), (B), (C), (E), (G), (M), (34)
Modiﬁed from [26].
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further evidence of the unique mechanism of
action of tigecycline.
Table 2 summarises initial in-vitro data for the
activity of tigecycline against recent clinical iso-
lates of bacteria collected from North American
and European medical institutions as part of the
ongoing TEST (Tigecycline Evaluation Surveil-
lance Trial) initiative. The TEST programme is a
3-year global surveillance initiative at 690 hospi-
tals in c. 35 countries [30,31] (45th Interscience
Congess for Antimicrobial Agents and Chemo-
therapy, abstracts E323, E326, E328, E331).
Against Esch. coli, tigecycline displayed equiv-
alent potency to imipenem, but both agents were
four-fold less potent than ceftriaxone or levoﬂ-
oxacin. Minocycline was only moderately active
against Esch. coli. Both Ent. aerogenes and
Ent. cloacae were susceptible to tigecycline
(MIC90s of 0.5 mg ⁄L and 1.0 mg ⁄L, respectively)
and, with the exception of levoﬂoxacin, tigecy-
cline displayed the highest potency against both
Ent. aerogenes and Ent. cloacae, with 4–128-fold
greater in-vitro activity than minocycline, ceftri-
axone or imipenem.
Ceftriaxone, levoﬂoxacin, imipenem and tige-
cycline had comparable activity against
Kleb. pneumoniae (MIC90 range 0.12–0.5 mg ⁄L).
However, for AmpC-producing strains of
Kleb. pneumoniae, tigecycline was 8–64-fold more
active than all other antimicrobial agents tested.
The markedly raised imipenem MIC90 of 32 mg ⁄L
for these strains probably represents a small num-
ber of isolates with changes in porin structure that
result in resistance to carbapenems. Interestingly,
theMIC90 of tigecyclinewas only raisedmarginally
(2 mg ⁄L), suggesting that these putative porin
alterations have little effect on tigecycline activity.
Isolates of Kleb. pneumoniae expressing an ESBL
were uniformly susceptible to imipenem
(MIC90 0.5 mg ⁄L), with similar potencies being
observed for tigecycline (MIC90 1.0 mg ⁄L) and
levoﬂoxacin (MIC90 1.0 mg ⁄L).
MIC90s of all agents for non-fermentative
Gram-negative bacterial species (A. baumannii,
Burkholderia cepacia, Steno. maltophilia and Ps. aeru-
ginosa) were generally ‡2 mg ⁄L. Tigecycline was
the most active compound tested against A. bau-
mannii (MIC90 2 mg ⁄L), being four-fold more
effective than minocycline, and at least eight-fold
more active than all other agents tested. Tigecy-
cline, minocycline and levoﬂoxacin were the most
effective agents against B. cepacia and Steno. malto-
Table 2. In-vitro activity of tigecy-
cline and comparator agents against
clinical isolates of selected Gram-
negative bacteria
Organism
(no. isolates tested) Antibiotic
MIC (mg/L)
Range 50% 90%
Escherichia coli
(100)
Tigecycline 0.06–0.5 0.12 0.25
Ceftriaxone £0.06 to >128 £0.06 £0.06
Imipenem £0.06–1 0.12 0.25
Levoﬂoxacin £0.06–16 £0.06 £0.06
Minocycline 0.12–32 0.5 8
Enterobacter cloacae
(100)
Tigecycline 0.25–2 0.5 1
Ceftriaxone £0.06 to >128 0.5 128
Imipenem 0.12–2 1 1
Levoﬂoxacin £0.06–1 £0.06 0.12
Minocycline 1–32 2 4
Klebsiella pneumoniae
(100)
Tigecycline 0.25–4 0.5 0.5
Ceftriaxone £0.06–128 £0.06 0.12
Imipenem £0.06–2 0.25 0.5
Levoﬂoxacin £0.06–16 £0.06 0.25
Minocycline 1–64 2 4
Klebsiella pneumoniae
AmpC producers
(29)
Tigecycline 0.5–2 1 2
Ceftriaxone 8 to >128 16 128
Imipenem 0.5–64 1 32
Levoﬂoxacin 1–64 1 64
Minocycline 2–32 4 16
Klebsiella pneumoniae
ESBL producers
(56)
Tigecycline 0.12–4 0.5 1
Ceftriaxone 2 to >128 16 64
Imipenem £0.06–2 0.25 0.5
Levoﬂoxacin £0.06–8 0.12 1
Minocycline 0.5 to >64 2 16
Acinetobacter baumannii
(97)
Tigecycline 0.03–4 0.25 2
Ceftriaxone 2 to >128 32 >128
Imipenem £0.06–32 0.25 32
Levoﬂoxacin £0.06–64 4 16
Minocycline £0.06–16 0.12 8
Pseudomonas aeruginosa
(100)
Tigecycline 0.25–32 8 16
Ceftriaxone 4 to >128 32 128
Imipenem 0.25–64 1 16
Levoﬂoxacin £0.06–64 0.25 4
Minocycline 0.25–64 8 32
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philia, with tigecycline, levoﬂoxacin and imipe-
nem displaying modest but higher activities
against Ps. aeruginosa than minocycline or ceftri-
axone.
Bacterial resistance among non-fermentative
Gram-negative bacilli, e.g., Acinetobacter spp.,
Steno. maltophilia, Ps. aeruginosa and B. cepacia, is
a signiﬁcant therapeutic challenge. Surveillance
involving 54 laboratories in the UK documented
the extent of antimicrobial resistance among
clinical isolates of Acinetobacter spp. [7]. Of 595
Acinetobacter isolates, 443 belonged to the A. bau-
mannii ‘complex’ (genomic groups 2, 3 and 13TU),
while the remaining 152 isolates belonged to
various other genomic groups. More recent sur-
veillance studies have conﬁrmed that isolates of
the A. baumannii complex are increasingly resist-
ant to cephalosporins, aminoglycosides, ﬂuoro-
quinolones and carbapenems [32,33].
During the past 5 years, the incidence of no-
socomial A. baumannii infections appears to have
increased. Observational data and surveillance
studies suggest that endemic, highly-resistant
strains of A. baumannii are particularly prevalent
among ICU patients [34,35]. Management of
infections in ICU patients caused by these strains
is particularly difﬁcult, as the strains often display
multiple drug resistance, including resistance to
carbapenems. A. baumannii acquires resistance by
a combination of mutation and gene transfer, and
is a common host for MBLs (carbapenemases)
belonging to the IMP and VIM families. The genes
for the IMP and VIM enzymes are carried within
integrons, which also carry gene cassettes confer-
ring resistance to aminoglycosides. When these
organisms also have chromosomal mutations
conferring ﬂuoroquinolone resistance, they are
now often susceptible only to polymyxins, which
have variable clinical efﬁcacy. Tigecycline was
found to have good in-vitro potency relative to
other major classes of antimicrobial agents, inclu-
ding aminoglycosides, cephalosporins, ﬂuoro-
quinolones and carbapenems, against clinical
isolates of A. baumannii obtained from institutions
across the UK during the year 2000 [7]. Agents
with MIC90 values £2 mg ⁄L at that time included
carbapenems, colistin, minocycline and tetracyc-
line. More recent data from Argentina show
tigecycline MIC90s of 2 mg ⁄L for all isolates of
Acinetobacter from patients with complicated
intra-abdominal infections; i.e., the drug is some
8–32-fold more active than comparator agents [36]
(Table 3). Tigecycline MIC90 values were compar-
able with those of imipenem ⁄ cilastatin (generally
two- to four-fold higher), and ranged from 0.5 to
2.0 mg ⁄L for all selected Gram-negative isolates
except Ps. aeruginosa, for which an MIC90 of
32 mg ⁄L was observed.
RESISTANCE TO GLYCYLCYCLINES
IN GRAM-NEGATIVE BACTERIA
The susceptibility data from the surveillance
studies summarised above show that some spe-
cies of Gram-negative bacteria are very rarely
resistant to tigecycline. Such species include
Esch. coli, Kleb. pneumoniae and Enterobacter spp.;
some other species, e.g., Ps. aeruginosa and the
Proteae (comprising the genera Proteus, Providen-
cia and Morganella), exhibit intrinsic decreased
susceptibility.
Detailed studies of the mechanism of tigecy-
cline resistance in Proteae have shown that it is
associated with changes in activity of the AcrAB
multidrug efﬂux pump. This drug-efﬂux system
belongs to the resistance–nodulation–division
non-speciﬁc family, and consists of a tripartite
complex of protein subunits located in the cell
wall that separates the inner- and outer-mem-
branes of Gram-negative bacteria [37,38]. The
system is capable of transporting a wide range
of drugs, detergents and dyes, e.g., acriﬂavin,
ﬂuoroquinolones, tetracyclines and chloramphen-
icol, and is subject to complex regulatory control.
Table 3. MIC range, MIC50 and
MIC90 of tigecycline and imi-
penem ⁄ cilastatin for selected clinical
isolates from patients with compli-
cated intra-abdominal infections
Isolate n
Tigecycline Imipenem/cilastatin
MIC range MIC50 MIC90 MIC range MIC50 MIC90
Bacteroides fragilis 83 0.06–16.0 1.0 2.0 0.12–4.0 0.25 0.50
Escherichia coli 350 0.06–1.0 0.25 0.5 0.12–1.0 0.12 0.25
Klebsiella pneumoniae 58 0.25–2.0 0.50 1.0 0.12–0.5 0.25 0.25
Pseudomonas aeruginosa 39 8.0–32.0 16.0 32.0 0.25–4.0 1.0 2.0
Enterobacter spp. 18 NA NA 1.0 NA NA 1.0
NA, not available.
Data collated from [36].
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Over-expression of pump components occurs
because of over-expression of transcriptional acti-
vators or inactivation of speciﬁc repressors
[37,38].
Transposon mutagenesis studies using the
EZ::TN system [39] with Morganella morganii
strain G1492, which has intermediate levels of
tigecycline resistance (MIC 4 mg ⁄L), generated
two independent susceptible (MIC 0.03 mg ⁄L)
knockout mutants with insertions at different
positions in the acrA gene [40]. DNA sequencing
of the acrRAB gene complex showed that acrA and
acrBwere transcribed divergently from a common
intergenic region, and that both were organised in
the same fashion as the corresponding genes in
Prot. mirabilis [39] and had 81% amino-acid
homology. Similar experiments in Prot. mirabilis
yielded insertions that mapped in acrB [39].
Plasmid complementation with acrRAB restored
drug resistance in both species, and the involve-
ment of AcrA ⁄B was conﬁrmed by northern
blotting and RT-PCR experiments [39,40].
In the case of Ps. aeruginosa, intrinsic low-level
resistance to tigecycline has been noted (mode
MIC 8 mg ⁄L) [11]. Using deﬁned mutations of
Ps. aeruginosa strain PA01 that were defective in
the production of both the MexAB–OprM and the
MexXY (OprM) efﬂux pumps [41], it was possible
to demonstrate that increased susceptibility to
tigecycline was associated with loss of MexXY,
and this was conﬁrmed by transcript analysis.
MexXY–OprM mutants plated on agar containing
tigecycline 4–6 mg ⁄L yielded easily recoverable
secondary mutants, one of which over-expressed
OprM and contained a 15-bp deletion in the
repressor gene mexR. MICs of narrow-spectrum
tetracyclines (doxycycline ⁄minocycline) were
much higher than those of tigecycline for these
over-expressing mutants, suggesting that
although glycylcyclines are removed from Ps. ae-
ruginosa by these pumps, they are not such good
substrates as the older compounds.
Species of Enterobacteriaceae that are found
only very rarely to be non-susceptible to tigecy-
cline have also been studied [42,43]. In all cases,
over-expression of acrAB, or a functional homo-
logue, was found to be responsible for non-
susceptibility, and this could be abolished by
transposon insertions in the acrA, acrB or ramA
genes; complementation by cloned plasmid-medi-
ated genes has also been demonstrated. Over-ex-
pression of the transcriptional activator ramA has
been associated with tigecycline resistance in
Kleb. pneumoniae [43]. Alternatively, deletion(s)
in the acrR repressor gene could result in dere-
pression of acrAB.
FUTURE PROSPECTS
The increasing frequency of Gram-negative path-
ogens displaying resistance to multiple classes of
antimicrobial agents is a cause for serious clinical
concern. Among the Enterobacteriaceae, resistant
strains of Esch. coli, Kleb. pneumoniae, Prot. mira-
bilis, C. freundii and Enterobacter spp., in partic-
ular, have contributed to increased patient
morbidity and mortality associated with nosoco-
mial infection. Also contributing to this trend is
the recently noted increase in resistance among
Acinetobacter spp., Steno. maltophilia and Ps. aeru-
ginosa, and the spread of ESBL CTX-M-type
enzymes among Esch. coli and Kleb. pneumoniae
isolates, particularly those from cases of bacter-
aemia [3,44–47]. Recent data demonstrate a clear
increase in the prevalence of ESBLs among iso-
lates of Esch. coli and Klebsiella spp. from cases of
bacteraemia, coupled with an increase in the
occurrence of CTX-M b-lactamases among isolates
of Esch. coli, Klebsiella spp. and Enterobacter spp.
[44]. There also appears to be a high correlation
between b-lactamase production and resistance to
both ciproﬂoxacin and gentamicin. In addition to
nosocomial disease, the occurrence of CTX-M
b-lactamases among community isolates of En-
terobacteriaceae, predominantly Esch. coli, is
being reported increasingly in association with
urinary tract infections [46,48]. In common with
nosocomial isolates, the ESBL-producing isolates
found in the community are also frequently
resistant to agents other than b-lactams.
Many drugs used empirically have become less
effective against nosocomial pathogens. For
example, third-generation cephalosporins often
display reduced effectiveness against ESBL-pro-
ducing enteric bacilli and high-level AmpC-pro-
ducing Enterobacter and Citrobacter spp. [4,6].
Recent data also suggest decreased susceptibility
to ﬂuoroquinolones among Gram-negative bacilli
infecting patients in ICUs [49]. However, there are
a number of antimicrobial agents, e.g., the carb-
apenems, b-lactam ⁄ b-lactamase inhibitor combi-
nations and cefepime, which can retain activity
against resistant strains of Enterobacteriaceae and
many strains of Acinetobacter, Steno. maltophilia
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and Ps. aeruginosa [50,51]. Nevertheless, although
these agents retain reasonably potent activity
against a broad range of Gram-negative bacteria,
the occurrence and spread of resistance to all of
these agents has been well-documented. The
necessary increased usage of these agents is likely
to select more resistance in the future.
The development of new antibacterial agents in
recent years has focused, to a large extent, on
agents for the treatment of infections caused by
Gram-positive bacteria. Compounds from classes
such as the oxazolidinones, streptogramins, ce-
phalosporins, glycopeptides, lipopeptides and
ﬂuoroquinolones have been targeted primarily
at staphylococcal infections (including methicil-
lin-resistant Staphylococcus aureus), enterococcal
infections (including vancomycin-resistant en-
terococci) and pneumococcal infections (including
multidrug-resistant Streptococcus pneumoniae).
Tigecycline remains a unique example of a
sentinel drug from a novel class of antimicrobial
agents, the glycylcyclines, which has potent
activity against both Gram-positive and Gram-
negative pathogens. Clinical studies have demon-
strated the efﬁcacy of tigecycline for the treatment
of complicated intra-abdominal and skin and
soft-tissue infections [36,52–54].
Recent surveillance initiatives have conﬁrmed
the potency of tigecycline against a broad spec-
trum of both Gram-positive and Gram-negative
pathogens [33,44,45,55]. The antibacterial activity
of tigecycline is largely unaffected by the resist-
ance mechanisms that occur most commonly in
Gram-negative bacteria. Tigecycline and carbap-
enems both retain activity against most organisms
with b-lactamase-mediated resistance, including
that mediated by ESBLs, e.g., CTX-M, in Entero-
bacteriaceae, and generally have good activity
against most clinically relevant isolates of Acine-
tobacter. Tigecycline also retains activity against
pathogens displaying efﬂux- or ribosomal-medi-
ated tetracycline resistance. Apart from those
Gram-negative bacteria that exhibit intrinsic
resistance, only rare examples of resistance,
involving up-regulation of efﬂux pump systems,
have been reported.
The microbiological efﬁcacy of tigecycline, cou-
pled with excellent pharmacokinetic and phar-
macodynamic properties of efﬁcacy and safety in
both animal studies and human clinical trials,
supports the potential therapeutic use of tigecy-
cline for the treatment of a range of infections
requiring initial or extended parenteral therapy.
Table 4 shows the percentage susceptibilities of
selected pathogens from a survey of ICU isolates
using breakpoints recommended by the US
Federal Drug Administration (FDA) and the
European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST). The clinical relevance of
the difference between the FDA and EUCAST
breakpoints will become apparent with time.
Despite these promising results, caution should
be exercised and widespread use of tigecycline
should be avoided to minimise the potential
development of resistance.
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